Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in BRAF Mutation-Positive NSCLC by Amanda J.W. Gibson, BSc (Hons), Aliyah Pabani, MD, Michelle L. Dean, BSc, Guillermo Martos, MD, Winson Y. Cheung, MD, MPH, FRCPC, Vishal Navani, M.B.B.S., MRCP, FRACP

Get full text

A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in Canada by Anifat A. Elegbede, MSc, MbChB, Amanda J. Gibson, BSc, Andrea S. Fung, PhD, MD, Winson Y. Cheung, MD, MPH, Michelle L. Dean, BSc, D. Gwyn Bebb, BMBCh, PhD, Aliyah Pabani, MD

Get full text

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors by Daniel E. Meyers, MD, MSc, Meghann Pasternak, MD, MSc, Samantha Dolter, MD, Heidi A.I. Grosjean, MD, Chloe A. Lim, MD, Igor Stukalin, MD, Siddhartha Goutam, MD, Vishal Navani, M.B.B.S., MRCP, Daniel Y.C. Heng, MD, MPH, Winson Y. Cheung, MD, PhD, Don G. Morris, MD, PhD, Aliyah Pabani, MD

Get full text